Insiders Updates
Nektar Therapeutics (NKTR) receives a Buy rating from H.C. Wainwright
Nektar Therapeutics’s recent filing unveils that its President & CEO ROBIN HOWARD W unloaded Company’s shares for reported $0.31 million
Menu
Nektar Therapeutics’s recent filing unveils that its President & CEO ROBIN HOWARD W unloaded Company’s shares for reported $0.31 million
Nektar Therapeutics’s filing revealed that its President & CEO ROBIN HOWARD W unloaded Company’s shares for reported $0.31 million on
In a filing, Nektar Therapeutics revealed its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $57693.0 on Sep
Nektar Therapeutics’s recently made public that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $19278.0 on Aug
Nektar Therapeutics’s recently made public that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $19278.0 on Aug
Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Nektar Therapeutics
Nektar Therapeutics’s filing revealed that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $7177.0 on May 19
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Nektar Therapeutics’s filing revealed that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $7177.0 on May 19
Nektar Therapeutics’s recent filing unveils that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $7177.0 on May